Labor Market Insights - The October ADP private-sector payroll report indicates an addition of +42K new jobs, surpassing expectations by +20K and reversing the previous month's downward revision of -29K [2] - Despite this positive report, the American labor market shows signs of decline, with an average gain of only +29K new jobs over the last four months, a decrease from +53K and +197K in the previous two four-month periods [3] Job Growth by Sector - Goods-producing jobs increased by +9K, while services jobs rose by +33K, with large firms (over 500 employees) contributing +73K to the job growth, contrasting with negative growth in small and medium-sized companies [4] - The Trade/Transportation/Utilities sector led job growth with +47K, followed by Education/Healthcare at +26K, while Leisure/Hospitality and Professional/Business Services saw declines of -6K and -15K respectively [5] Wage Trends - Wage gains for job stayers averaged +4.5%, while job changers saw an increase of +6.7%, indicating a narrowing historical gap and suggesting less urgency for employees to seek new positions [6] Company Earnings Reports - McDonald's (MCD) reported earnings of $3.22 per share, missing estimates of $3.35, but same-store sales increased by +3.6%, leading to a +3% rise in pre-market trading [7] - Humana (HUM) exceeded earnings expectations with $3.24 per share, a +11.34% beat, and revenues of $32.65 billion, but lowered guidance caused shares to drop by -5.5% [8] - Aurora Cannabis (ACB) reported earnings of $0.09 per share, a +200% surprise compared to expectations, with record quarterly revenues of $70.5 million, up +15% year-over-year, resulting in a +9% increase in pre-market trading [9]

Core Insights - International Flavors (IFF) reported a revenue of $2.69 billion for the quarter ended September 2025, reflecting a year-over-year decline of 7.9% [1] - The earnings per share (EPS) for the same period was $1.05, slightly up from $1.04 a year ago, with an EPS surprise of +2.94% compared to the consensus estimate of $1.02 [1] Revenue Performance - Net Sales in Health & Biosciences reached $577 million, exceeding the average estimate of $568.61 million, marking a +1.2% change year-over-year [4] - Net Sales in Scent amounted to $652 million, surpassing the average estimate of $618.57 million, representing a +6.4% change year-over-year [4] - Net Sales in Taste were $635 million, slightly above the average estimate of $628.17 million [4] - Net Sales in Food Ingredients totaled $830 million, also exceeding the average estimate of $825.94 million [4] Adjusted Operating EBITDA - Adjusted Operating EBITDA for Health & Biosciences was $150 million, compared to the average estimate of $143.03 million [4] - Adjusted Operating EBITDA for Food Ingredients was $106 million, slightly below the average estimate of $109.32 million [4] - Adjusted Operating EBITDA for Taste was $128 million, marginally above the average estimate of $126.56 million [4] - Adjusted Operating EBITDA for Scent was $135 million, exceeding the average estimate of $129.4 million [4] Stock Performance - Shares of International Flavors have returned +0.9% over the past month, while the Zacks S&P 500 composite has changed by +2.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Harley-Davidson Inc. reported third-quarter results that exceeded Wall Street expectations, indicating a strong performance despite underlying challenges in its core motorcycle business [1] Financial Performance - The company's third-quarter results showed a positive trend, surpassing analyst forecasts, which reflects a resilient financial position [1] - Specific figures regarding revenue and profit margins were not detailed in the provided text, but the overall performance was noted as better than anticipated [1] Business Challenges - Despite the strong quarterly results, the motorcycle segment faces significant challenges that could impact future growth [1] - The underlying issues in the core motorcycle business suggest potential risks that need to be monitored closely [1]

Company Overview - Franklin Resources, Inc. (BEN) is an asset management company with a market cap of $11.7 billion, based in San Mateo, California, offering a wide range of investment solutions across more than 150 countries [1] Performance Analysis - Over the past 52 weeks, BEN has gained 8.3%, underperforming the S&P 500 Index, which surged 17.7% [2] - Year-to-date, BEN's stock is up 11.2%, compared to the S&P 500's 16.6% increase [2] - BEN has also lagged behind the iShares U.S. Financial Services ETF (IYG), which returned 19.3% over the past 52 weeks and 13.2% year-to-date [3] Earnings Report - On August 1, BEN's shares declined slightly after its Q3 earnings release, despite reporting better-than-expected performance with operating revenue of $2.1 billion and adjusted EPS of $0.49, both exceeding analyst estimates [4] - The company's overall top line declined 2.8% year-over-year due to lower investment management fees, while adjusted EPS fell by 18.3% from the previous year [4] Future Earnings Expectations - Analysts expect BEN's EPS to decline 11.3% year-over-year to $2.12 for the current fiscal year ending in September [5] - The earnings surprise history for BEN is mixed, with the company exceeding or meeting consensus estimates in three of the last four quarters [5] Analyst Ratings - Among 13 analysts covering BEN, the consensus rating is a "Hold," consisting of three "Strong Buy," five "Hold," one "Moderate Sell," and four "Strong Sell" ratings [5] - Barclays maintained an "Underweight" rating on BEN and lowered its price target to $20, while the mean price target of $24.67 suggests a 9.1% premium from current price levels [6] - The Street-high price target of $31 indicates an upside potential of 37.1% [6]

Core Insights - Portland General Electric Co. reported better-than-expected third-quarter earnings with adjusted earnings of $1.00 per diluted share, surpassing the consensus forecast of $0.98 [2] - Revenue for the quarter was $952 million, slightly below estimates of $975.7 million, but showed an increase from $929 million in the same quarter last year, driven by strong demand from data center customers [2] Financial Performance - The company achieved a 13% increase in industrial load from the previous quarter, indicating robust demand [2] - The reaffirmed 2025 adjusted earnings guidance is set between $3.13 to $3.33 per share, aligning with the analyst consensus of $3.23 [3] Strategic Initiatives - Portland General Electric is advancing its resource procurement strategy and has requested regulatory acknowledgment for an updated shortlist of bidders under its 2023 All-Source Request for Proposal [3] - The company anticipates finalizing contracts by early 2026, with new projects expected to commence service by the end of 2027 [3]

Core Insights - Flowserve Corp. (NYSE:FLS) has achieved significant stock performance, reaching an all-time high driven by strong earnings and positive cash flow projections from a subsidiary divestment [1][3]. Financial Performance - The company reported a 277% increase in attributable net income for Q3, amounting to $219 million compared to $58 million in the same quarter last year [3]. - Sales increased by 3.5% year-on-year, rising to $1.17 billion from $1.13 billion [3]. Future Outlook - For the full-year 2025, Flowserve raised its adjusted EPS forecast to a range of $3.40 to $3.50, up from a previous range of $3.25 to $3.40 [4]. - However, the company revised its total sales growth expectations down to 4-5% from 5-6%, and organic sales growth to around 2% from 3-4% [4]. Strategic Moves - Flowserve announced the divestment of its subsidiary BW/IP – New Mexico, Inc., which holds asbestos liabilities, to an affiliate of Acorn Investment Partners. This transaction is expected to close in Q4 2025 and enhance free cash flow by approximately $15 million to $20 million annually [5].

Core Insights - Edison International (EIX) reported third-quarter 2025 adjusted earnings of $2.34 per share, exceeding the Zacks Consensus Estimate of $2.16 by 8.3%, and reflecting a 55% increase from $1.51 in the same quarter last year [1] - The company's total operating revenues for the third quarter reached $5.75 billion, surpassing the Zacks Consensus Estimate of $5.61 billion by 2.6%, and marking a 10.6% increase from $5.2 billion in the prior year [2] Financial Performance - Total operating expenses increased by 2.7% year over year to $4.32 billion, with purchased power and fuel costs decreasing by 10.4%, while depreciation and amortization expenses rose by 21.4% [3] - Operating income for the quarter was $1.43 billion, compared to $0.99 billion in the previous year [4] Segment Results - Southern California Edison reported adjusted earnings of $2.58 per share, up from $1.74 in the year-ago quarter, attributed to higher revenues from the 2025 GRC final decision [5] - The Edison International Parent and Other segment incurred an adjusted loss of 24 cents per share, slightly worse than the loss of 23 cents in the prior year due to increased interest expenses [5] Financial Update - As of September 30, 2025, cash and cash equivalents stood at $364 million, up from $193 million at the end of 2024 [6] - Long-term debt increased to $34.48 billion from $33.53 billion at the end of 2024 [6] - Net cash flow from operating activities for the first nine months of 2025 was $4.23 billion, compared to $3.84 billion in the same period last year [6] Capital Expenditures - Total capital expenditures for the company were $4.62 billion as of September 30, 2025, an increase from $4.21 billion in the previous year [7] Guidance - The company narrowed its 2025 earnings per share guidance to a range of $5.95-$6.20, compared to the previous range of $5.94-$6.34, with the Zacks Consensus Estimate currently at $6.10 per share [9][10] Zacks Rank - Edison International currently holds a Zacks Rank 1 (Strong Buy) [11]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - UnitedHealth Group has experienced a 28% decline in share value in 2025 thus far [4] - The company reported adjusted earnings of $2.92 per share for Q3, exceeding analysts' expectations of $2.74 per share [3] - Revenue for the third quarter grew by 12% year-over-year to $113.16 billion, aligning with market expectations [3] - UnitedHealth raised its full-year adjusted earnings per share outlook to at least $16.25, up from a previous estimate of at least $16 [3] Business Performance - The recent earnings report indicates signs of improvement in UnitedHealth's business health after facing several setbacks earlier in the year [2][5] - The company has undergone leadership changes and faced regulatory scrutiny, which contributed to earlier stock declines [6][7] - CEO Stephen Hemsley emphasized the company's focus on strengthening performance and positioning for growth in 2026 and beyond [7] Market Reaction - Following the earnings announcement, UnitedHealth's shares initially surged before retracting some gains [4] - The better-than-expected earnings may signal a return to stability for the company after a turbulent period [5]

Core Insights - Regeneron Pharmaceuticals reported third-quarter adjusted earnings of $11.83 per share, a 5% decrease year-over-year, surpassing the consensus estimate of $9.59 [1] - The company achieved sales of $3.75 billion, reflecting a 1% year-over-year increase and exceeding the consensus of $3.59 billion [1] - U.S. net sales for Eylea HD and Eylea fell 28% year-over-year to $1.12 billion, with Eylea HD contributing $431 million and Eylea contributing $681 million [1] Sales Performance - Eylea HD sales increased due to higher volumes driven by stronger demand, although this was partially offset by a lower net selling price [2] - Eylea sales were negatively impacted by lower volumes due to competitive pressures, market share loss to compounded bevacizumab, and patient transitions to Eylea HD [2] Collaboration Revenue - Sanofi collaboration revenue rose 28% to $1.62 billion, primarily due to increased profits from antibody commercialization, which amounted to $1.46 billion in Q3 2025 compared to $1.09 billion in Q3 2024 [3] Pipeline Developments - The FDA issued a Complete Response Letter (CRL) for the prefilled syringe supplemental BLA, citing unresolved inspection findings at Catalent [4] - Regeneron plans to submit an application by January 2026 to include a new prefilled syringe manufacturing filler in the Eylea HD BLA [4] - A supplement application is under FDA review for EYLEA HD every-four-week dosing, with a target action date in late November 2025 [5] Financial Outlook - Regeneron expects a 2025 GAAP gross margin of approximately 82%, down from prior guidance of 83%, while reaffirming an adjusted gross margin of approximately 86% [6] - REGN stock rose 3.96% to $608.50 in premarket trading [6]